Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
      • Real World Data
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Corporate

Corporate

Evaluate

Thumbnail
August 01, 2023

Keytruda and Gardasil lead Merck's earnings beat

Thumbnail
July 28, 2023

Biogen hopes to bridge the gap with $7.3bn Reata buy

Biogen’s acquisition of rare neurological disease player Reata provides a much needed near-term sales lift, but at a price.

Article image
Vantage logo
June 26, 2023

Hidradenitis suppurativa promise sends Moonlake soaring

Strong mid-stage data seem to show sonelokimab, a Merck KGaA cast-off, beating bigger rivals.

Article image
Vantage logo
June 22, 2023

Roivant rises on growing hopes for novel immunology mechanism

Article image
Vantage logo
June 16, 2023

Coherus brings the Surface saga to a close

Article image
Vantage logo
June 15, 2023

Aldeyra chalks up pivotal win and awaits partnering news

Article image
Vantage logo
June 14, 2023

Unpartnered assets: on the shelf or hidden treasure?

A look at biopharma’s most highly valued yet unpartnered assets features Karuna, Ventyx and regular bridesmaid Ascendis.

Article image
Vantage logo
June 12, 2023

Illumina’s divestment of Grail creeps closer

Article image
Vantage logo
June 06, 2023

Asco 2023 – early first-line lung cancer data mined for datopotamab gold

The search is on for signals in front-line use, where Daiichi Sankyo and Astrazeneca have already bet big with the Trop2-targeted project.

Article image
Vantage logo
June 05, 2023

Asco 2023 – Bicara eyes head and neck niche

Impressive data in HPV-negative disease, potentially beating Keytruda, has the private group making pivotal plans.

Article image
Vantage logo
June 02, 2023

Asco 2023 – Novartis’s adjuvant breast cancer win comes with caveats

The Natalee trial hits in all-comers, but an equivocal showing in node-negative patients raises questions about market expansion.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up